Repurposing Valsartan to Protect the Right Heart in Pulmonary Hypertension
Official title: REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension
Funded at University of Washington · NIH-11380541 · Data updated 2026-11-12
Aims to reuse valsartan, an ACE/angiotensin receptor blocker, to help the right heart in pulmonary hypertension patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | June 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $655,921 |
| NIH project number | 5R33HL167848-04 |
| Project ID | NIH-11380541 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with pulmonary arterial hypertension or related right heart failure who could tolerate angiotensin receptor blockade.
✕Less likely to help
Patients with contraindications to valsartan or those not affected by right heart remodeling may not benefit.
What this research studies
This project explores whether a well-known blood pressure medicine called valsartan can protect the right heart in people with pulmonary hypertension, potentially improving outcomes even when the lung disease is not getting worse. Researchers combine prior animal data and real-world observations suggesting angiotensin signaling affects heart remodeling and survival. The work builds on existing knowledge about repurposing affordable drugs to rapidly translate findings into patient care. The study focuses on adults with PAH who may benefit from therapies targeting the right heart muscle.
Why it matters
Potential benefit: If successful, this approach could provide a readily available treatment to protect the right heart and reduce complications for people with PAH.
How similar studies have gone: Observational data and animal studies suggest potential benefits, but randomized human结果 are needed for confirmation.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Leary, Peter J — University of Washington
- Study coordinator: Leary, Peter J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
-
CD4 T Cells, Schistosoma, and Pulmonary Hypertension: Understanding How Immune Cells Drive Disease
A human-health focused study uses a mouse model and human samples to explore how immune cells and inflammation may contribute to a lung blood vessel disease linked to schistosomiasis.
-
CD4 T Cells and Schistosoma-Related Pulmonary Hypertension
A study to understand how specific immune cells behave in a lung complication caused by schistosomiasis, with the goal of finding targets to prevent or treat it.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Right heart remodeling in pulmonary hypertension
In people with pulmonary hypertension, researchers are studying how the right side of the heart changes and why it fails, with the goal of finding new treatments.
-
TEMPO-PH: How the right heart adapts in pulmonary hypertension over time
A study to build a detailed molecular portrait of why the right side of the heart fails in pulmonary hypertension and how a common heart medicine might help.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.